EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+1.57%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.61B
AUM Growth
+$36.4M
(+2.3%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
6.47%
Top 10 Holdings %
Top 10 Hldgs %
61.46%
Holding
387
New
81
Increased
131
Reduced
147
Closed
19
Top Buys
| 1 |
ASE Group
ASX
|
$25.3M |
| 2 |
Microsoft
MSFT
|
$12.9M |
| 3 |
NVIDIA
NVDA
|
$11.9M |
| 4 |
Apple
AAPL
|
$9.18M |
| 5 |
Amazon
AMZN
|
$7.47M |
Top Sells
| 1 |
Sea Limited
SE
|
$24.3M |
| 2 |
Advanced Micro Devices
AMD
|
$16.8M |
| 3 |
TSMC
TSM
|
$8M |
| 4 |
Weibo
WB
|
$2.43M |
| 5 |
Pinduoduo
PDD
|
$2.4M |
Sector Composition
| 1 | Consumer Discretionary | 40.2% |
| 2 | Technology | 29.79% |
| 3 | Communication Services | 9.9% |
| 4 | Healthcare | 5.71% |
| 5 | Real Estate | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Cigna
CI
$80.8B
| $348K | 0.02% |
959
+6
| +0.6% | +$2.18K |
|
|
SAGE
252
DELISTED
Sage Therapeutics
SAGE
| $348K | 0.02% |
18,544
+2,062
| +13% | +$38.6K |
|
253
Electronic Arts
EA
$41.8B
| $345K | 0.02% |
2,604
-43
| -2% | -$5.71K |
|
254
Bristol-Myers Squibb
BMY
$95B
| $344K | 0.02% |
6,350
+731
| +13% | +$39.6K |
|
255
Acadia Pharmaceuticals
ACAD
$4.32B
| $342K | 0.02% |
18,488
-4,405
| -19% | -$81.4K |
|
256
CVS Health
CVS
$93.2B
| $339K | 0.02% |
4,255
+597
| +16% | +$47.6K |
|
257
Viridian Therapeutics
VRDN
$1.49B
| $338K | 0.02% |
19,323
+8,448
| +78% | +$148K |
|
258
Biomea Fusion
BMEA
$107M
| $338K | 0.02% |
+22,605
| New | +$338K |
|
|
INBX
259
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $334K | 0.02% |
9,544
+4,032
| +73% | +$141K |
|
260
Verisk Analytics
VRSK
$37.5B
| $333K | 0.02% |
1,413
-31
| -2% | -$7.31K |
|
261
ImmunityBio
IBRX
$2.2B
| $333K | 0.02% |
61,922
+22,428
| +57% | +$120K |
|
262
Baker Hughes
BKR
$46B
| $331K | 0.02% |
9,886
-133
| -1% | -$4.46K |
|
263
Boston Scientific
BSX
$160B
| $330K | 0.02% |
4,823
+216
| +5% | +$14.8K |
|
264
AstraZeneca
AZN
$253B
| $330K | 0.02% |
4,871
-141
| -3% | -$9.55K |
|
265
Protagonist Therapeutics
PTGX
$3.64B
| $327K | 0.02% |
11,304
+2,347
| +26% | +$67.9K |
|
266
Trade Desk
TTD
$25.4B
| $325K | 0.02% |
3,723
-118
| -3% | -$10.3K |
|
267
Veracyte
VCYT
$2.45B
| $323K | 0.02% |
14,581
+6,016
| +70% | +$133K |
|
268
C4 Therapeutics
CCCC
$187M
| $322K | 0.02% |
+39,396
| New | +$322K |
|
269
Mirum Pharmaceuticals
MIRM
$3.71B
| $316K | 0.02% |
12,583
+5,582
| +80% | +$140K |
|
270
Kura Oncology
KURA
$701M
| $314K | 0.02% |
+14,710
| New | +$314K |
|
271
Agios Pharmaceuticals
AGIO
$2.08B
| $306K | 0.02% |
+10,453
| New | +$306K |
|
272
Arcus Biosciences
RCUS
$1.22B
| $303K | 0.02% |
16,052
+2,551
| +19% | +$48.2K |
|
273
Disc Medicine
IRON
$2.09B
| $303K | 0.02% |
+4,861
| New | +$303K |
|
274
Xcel Energy
XEL
$42.6B
| $294K | 0.02% |
5,479
-15
| -0.3% | -$806 |
|
275
Becton Dickinson
BDX
$54.6B
| $291K | 0.02% |
1,177
+163
| +16% | +$40.3K |
|